![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Souza Elaine Cristina Lima de Ferreira Andrea Claudia Freitas Carvalho Denise Pires de
Publisher: Informa Healthcare
ISSN: 1472-8222
Source: Expert Opinion on Therapeutic Targets, Vol.15, Iss.9, 2011-09, pp. : 1099-1112
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets, Vol. 4, Iss. 8, 2004-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
mTOR inhibitors in the treatment of cancer
By Fasolo Angelica Sessa Cristiana
Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
Current Cancer Drug Targets, Vol. 8, Iss. 8, 2008-12 ,pp. :